Stock Analysis·← Pickers

ENGNW

enGene Holdings Inc. Warrants

enGene Holdings Inc. Warrants (ENGNW) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 47.0, with 0/3 trend checks passing.

Price
$0.21
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
47.0
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

ENGNW with MA50 and MA200

4.203.182.161.140.1206/0410/0901/1504/1407/15
ENGNW2025-06-042026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$0.91-63.75% vs price
MA200
$1.99-83.42% vs price
RSI (14)
47.0Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for ENGNW

enGene Holdings Inc. Warrants (ENGNW) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.21, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 63.8% and below the 200-day moving average by 83.4%.

Momentum and stretch context

ENGNW currently has an RSI reading of 47.0, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

For traders reviewing ENGNW next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About enGene Holdings Inc. Warrants

EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.

Sector
Healthcare
Industry
Biotechnology
CEO
Ronald H. W. Cooper
Employees
81
Market cap
$10.8M
Beta
-0.28
52-week range
$0.21 – $2.10
Dividend
No
Exchange
NASDAQ
Country
CA
IPO date
1 Feb 2022
ISIN
CA29286X1197
CUSIP
29286X119
Website
engene.com
Company profile data from Financial Modeling Prep. ENGNW listed on NASDAQ.
Share dilution

ENGNW shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Dec 2021Apr 2026
Shares outstanding (latest)
69.7M
Since Dec 2021
+340.9%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. ENGNW18 data points from Dec 2021 to Apr 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about ENGNW

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.